It may not be ideal to directly tally export data with actual numbers, I have some concerns regarding margins over the last two quarters. Despite strong shipments of Bempedoic Acid and Xanomeline, margins have remained under pressure. If anyone can shed light on this, it would be helpful. Can we expect margins to normalize to the 28-30% range by FY26/FY27 as sales from these products scale up?
@phreakv6 has provided valuable insights on this, but any additional analysis or perspectives would be greatly appreciated.